-
Vaccines, Blood & Biologics
ProQuad
Proper Name: Measles, Mumps, Rubella and Varicella Virus Vaccine Live
Tradename: ProQuad
Manufacturer: Merck & Co, Inc, License #0002
Indication:
- For vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age
-
Product Information
- Package Insert - Refrigerator-Stable Formulation - ProQuad (PDF - 706KB)
October 29, 2009 - Package Insert - Frozen Formulation - ProQuad (PDF - 680KB)
October 29, 2009
-
-
Supporting Documents
- October 29, 2009 Approval Letter - ProQuad
Supplement: To include concomitant administration with hepatitis A vaccine (VAQTA) and/or pneumococcal conjugate vaccine (Prevnar), and use of ProQuad in children 15 mos to 12 yrs if a second dose of measles, mumps, rubella, varicella is needed. - February 27, 2008 Approval Letter - ProQuad
Package Insert Revisions - Information Pertaining to Labeling Revision for ProQuad - Measles, Mumps, Rubella and Varicella Virus Vaccine Live
February 27, 2008 - September 6, 2005 Approval Letter - ProQuad
Indication: For vaccination against measles, mumps, rubella and varicella in children 12 months to 12 years of age. - Clinical Review - ProQuad (PDF - 2574KB)
August 25, 2005
-
-
Related Links
- What Clinicians Need to Know About MMRV Vaccine Safety (CDC)
Centers for Disease Control and Prevention
-
Contact Us
Consumer Affairs Branch (CBER)
- (800) 835-4709
- (301) 827-1800
- ocod@fda.hhs.gov
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448
-
-
-